551 results on '"Gardoni, Fabrizio"'
Search Results
2. Missense variants in RPH3A cause defects in excitatory synaptic function and are associated with a clinically variable neurodevelopmental disorder
3. Reciprocal cortico-amygdala connections regulate prosocial and selfish choices in mice
4. Glutamatergic Treatments for Parkinson’s Disease
5. Antidepressant-induced increase in GluA2 expression does not translate in changes of AMPA receptor-mediated synaptic transmission at CA3/CA1 synapses in rats
6. Rabphilin-3A as a novel target to reverse α-synuclein-induced synaptic loss in Parkinson’s disease
7. GluA3 autoantibodies induce alterations in dendritic spine and behavior in mice
8. Synaptic dysfunction in early phases of Alzheimer's Disease
9. Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia
10. Anti-GluA3 antibodies in frontotemporal dementia: effects on glutamatergic neurotransmission and synaptic failure
11. Loss of Ryanodine Receptor 2 impairs neuronal activity-dependent remodeling of dendritic spines and triggers compensatory neuronal hyperexcitability
12. Linking NMDA Receptor Synaptic Retention to Synaptic Plasticity and Cognition
13. Detection of TDP‐43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia
14. The Synaptonuclear Messenger RNF10 Acts as an Architect of Neuronal Morphology
15. Amyloid-β Oligomers Regulate ADAM10 Synaptic Localization Through Aberrant Plasticity Phenomena
16. Intensive exercise ameliorates motor and cognitive symptoms in experimental Parkinson’s disease restoring striatal synaptic plasticity
17. Glutamatergic mechanisms in l-DOPA-induced dyskinesia and therapeutic implications
18. Detrimental effects of soluble α-synuclein oligomers at excitatory glutamatergic synapses
19. Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19
20. Intensive exercise ameliorates motor and cognitive symptoms in experimental Parkinson's disease restoring striatal synaptic plasticity
21. Correction: Loss of Ryanodine Receptor 2 impairs neuronal activity-dependent remodeling of dendritic spines and triggers compensatory neuronal hyperexcitability
22. The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients
23. d-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain
24. Targeting glutamatergic synapses in Parkinson's disease
25. Anti-GluA3 autoantibodies recapitulate frontotemporal dementia with synaptic loss and tau accumulation: from animal model to rescue strategy
26. Early maternal deprivation immunologically primes hippocampal synapses by redistributing interleukin-1 receptor type I in a sex dependent manner
27. Molecular pathogenesis of Alzheimer’s disease in human peripheral cells: platelets show it all!
28. The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease
29. NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and α-Synuclein Proteinopathies
30. NMDA receptors
31. Aβ leads to Ca2+ signaling alterations and transcriptional changes in glial cells
32. Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism
33. Detrimental effects of soluble a-synuclein oligomers at excitatory glutamatergic synapses.
34. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias
35. Rabphilin-3A Drives Structural Modifications of Dendritic Spines Induced by Long-Term Potentiation
36. Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate l-DOPA-induced dyskinesia
37. Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinson’s and Alzheimer’s Disease Patients
38. Synaptic Neurofilaments and GluN1-Neurofilament Light Chain Interaction in Experimental Models of α-Synucleinopathies
39. Interferon-β1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors
40. Searching for new animal models of Alzheimer′s disease
41. Control of protein synthesis and memory by GluN3A-NMDA receptors through inhibition of GIT1/mTORC1 assembly
42. Author response: Control of protein synthesis and memory by GluN3A-NMDA receptors through inhibition of GIT1/mTORC1 assembly
43. GluA3-containing AMPA receptors: From physiology to synaptic dysfunction in brain disorders
44. Control of protein synthesis and memory by GluN3A-NMDA receptors through inhibition of GIT1/mTORC1 assembly
45. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinsonʼs disease
46. Alzheimerʼs disease and modern lifestyle: what is the role of stress?
47. Zinc transporter-1: a novel NMDA receptor-binding protein at the postsynaptic density
48. Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
49. Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease
50. Transcranial Magnetic Stimulation Exerts “Rejuvenation” Effects on Corticostriatal Synapses after Partial Dopamine Depletion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.